Tech Company Financing Transactions
Neomorph Funding Round
Deerfield Capital participated in a $109 million Series A funding round for Neomorph. The round was announced on 12/23/2020.
Transaction Overview
Company Name
Announced On
12/23/2020
Transaction Type
Venture Equity
Amount
$109,000,000
Round
Series A
Investors
Deerfield Capital (Cameron Wheeler)
Proceeds Purpose
This Series A financing will position Neomorph to further develop its platform, advance lead programs, and expand the research team.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5590 Morehouse Dr.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Neomorph is a venture backed biotechnology company based in San Diego, California. The team at Neomorph is building a leading protein degradation company, focusing on molecular glue degraders. Our mission at Neomorph is to use this technology to solve critical problems in human health by the discovery and development of innovative new medicines against undruggable targets.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Scientific Officer
Philip Chamberlain
Founder
Scott Armstrong
Founder
Benjamin Ebert
Founder
Eric Fischer
Vice President
Rohan Beckwith
Vice President
Gang Lu
Vice President
Benjamin Wen
VP - R & D
Samer Chmait
Browse more venture capital transactions:
Prev: 12/23/2020: SomaLogic venture capital transaction
Next: 12/23/2020: Atriomx Health venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. All VC database entries on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs